Meitav Investment House Ltd. Trims Stock Position in InMode Ltd. (NASDAQ:INMD)

Meitav Investment House Ltd. cut its holdings in InMode Ltd. (NASDAQ:INMD - Free Report) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,334,405 shares of the healthcare company's stock after selling 17,403 shares during the quarter. Meitav Investment House Ltd. owned approximately 1.59% of InMode worth $22,269,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Systematic Financial Management LP boosted its stake in InMode by 13.3% in the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company's stock worth $16,647,000 after purchasing an additional 115,492 shares in the last quarter. Barclays PLC boosted its stake in InMode by 113.5% in the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock worth $2,876,000 after purchasing an additional 90,173 shares in the last quarter. Hotchkis & Wiley Capital Management LLC boosted its stake in InMode by 12.9% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 720,750 shares of the healthcare company's stock worth $12,217,000 after purchasing an additional 82,100 shares in the last quarter. State Street Corp boosted its stake in InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock worth $34,657,000 after purchasing an additional 73,183 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in InMode in the 3rd quarter worth about $1,104,000. 68.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research note on Tuesday, February 4th. Barclays upped their target price on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $22.25.

InMode Stock Down 0.4 %

INMD traded down $0.07 during midday trading on Friday, hitting $18.90. 755,211 shares of the company traded hands, compared to its average volume of 905,765. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $23.46. The firm has a market capitalization of $1.31 billion, a PE ratio of 8.04 and a beta of 2.13. The company's 50-day moving average is $17.39 and its 200 day moving average is $17.29.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.